Andrew Callos, Executive Vice President, Chief Commercial Officer, on July 30, 2026, sold 14,000 shares in Cytokinetics (CYTK) for $1,118,320. Following the Form 4 filing with the SEC, Callos has control over a total of 58,555 common shares of the company, with 58,555 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1061983/000106198326000086/xslF345X05/form4.xml
Jerry J. Baack, Director, CEO, on July 27, 2026, sold 27,234 shares in Bridgewater Bancshares (BWB) for $567,764. Following the Form 4 filing with the SEC, Baack has control over a total of 1,161,769 common shares of the company, with 1,158,769 shares held directly and 3,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1341317/000173312626000007/xslF345X05/form4-07292026_090700.xml
Mohamed Abdelsadek, Executive Vice President, Chief Global Solutions Officer, on July 28, 2026, sold 23,495 shares in TransUnion (TRU) for $1,997,075. Following the Form 4 filing with the SEC, Abdelsadek has control over a total of 57,182 common shares of the company, with 57,182 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1552033/000205864826000006/xslF345X05/wk-form4_1785361075.xml
Jeffrey G. Ludwig, Director, President & CEO, on July 28, 2026, sold 8,383 shares in Midland States Bancorp (MSBI) for $285,023. Following the Form 4 filing with the SEC, Ludwig has control over a total of 412,540 common shares of the company, with 400,971 shares held directly and 11,569 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1466026/000146602626000072/xslF345X05/primary_01.xml